Drug Profile
Carlumab
Alternative Names: Anti-CCL2 monoclonal antibody Centocor; Anti-chemokine ligand 2 monoclonal antibody Centocor; Anti-MCP-1 monoclonal antibody Centocor; Anti-monocyte chemoattractant protein 1-monoclonal antibody Centocor; Anti-monocyte chemotactic protein 1 monoclonal antibody Centocor; CNTO-888; Fully human antibody therapeutic for immunology/oncology - Janssen Biotech/MorphoSysLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MorphoSys
- Developer Janssen Biotech
- Class Antifibrotics; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Chemokine CCL2 inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Idiopathic pulmonary fibrosis; Ovarian cancer; Prostate cancer; Solid tumours